897b2bdb-db71-43e1-a4a1-db03860e257a.pdf Appendix 4C Quarterly report for entities admitted on the basis of commitments

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10

Name of entity

Rule 4.7B

ResApp Health Limited (formerly Narhex Life Sciences Limited)

ABN Quarter ended ("current quarter")

51 094 468 318

31 March 2016

Consolidated statement of cash flows

Current quarter

$A'000

Year to date (9 months)

$A'000

- (141)

(30)

(298)

- (160)

- 18

(1)

-

-

- (331)

(82)

(853)

- (502)

- 40

(1)

-

-

(612)

(1,728)

Cash flows related to operating activities

  1. Receipts from customers

  2. Payments for (a) staff costs

    1. advertising & marketing

    2. research & development

    3. leased assets

    4. other working capital

    5. Dividends received

    6. Interest and other items of a similar nature received

    7. Interest and other costs of finance paid

    8. Income taxes paid

    9. Other (provide details if material)

    Net operating cash flows

    Current quarter

    $A'000

    Year to date (9 months)

    $A'000

    1.8

    Net operating cash flows (carried forward)

    (612)

    (1,728)

    Cash flows related to investing activities

    -

    -

    1.9

    Payment for acquisition of:

    (a) businesses (item 5)

    (b) equity investments

    -

    -

    (c) intellectual property

    -

    -

    (d) physical non-current assets

    -

    -

    (e) other non-current assets

    -

    -

    1.10

    Proceeds from disposal of:

    (a) businesses (item 5)

    -

    -

    (b) equity investments

    -

    -

    (c) intellectual property

    -

    -

    (d) physical non-current assets

    -

    -

    (e) other non-current assets

    -

    -

    1.11

    Loans to other entities

    -

    -

    1.12

    Loans repaid by other entities

    -

    -

    1.13

    Other - Cash acquired from ResApp Diagnostics Pty Ltd.

    -

    32

    Net investing cash flows

    -

    32

    1.14

    Total operating and investing cash flows

    (612)

    (1,696)

    Cash flows related to financing activities

    475

    480

    1.15

    Proceeds from issues of shares, options, etc.

    1.16

    Proceeds from sale of forfeited shares

    -

    -

    1.17

    Proceeds from borrowings

    -

    -

    1.18

    Repayment of borrowings

    -

    -

    1.19

    Dividends paid

    -

    -

    1.20

    Other - capital raising costs

    -

    (338)

    Net financing cash flows

    475

    142

    Net increase (decrease) in cash held

    (137)

    (1,554)

    1.21

    Cash at beginning of quarter/year to date

    2,681

    4,098

    1.22

    Exchange rate adjustments to item 1.20

    -

    -

    1.23

    Cash at end of quarter

    2,544

    2,544

    Payments to directors of the entity and associates of the directors Payments to related entities of the entity and associates of the related entities

    Current quarter

    $A'000

    1.24

    Aggregate amount of payments to the parties included in item 1.2

    147

    1.25

    Aggregate amount of loans to the parties included in item 1.11

    -

    1.26

    Explanation necessary for an understanding of the transactions

    1. Director fees to non-executive directors and salary to managing director, including superannuation;

    2. Accounting, company secretarial and office services;

    3. Consultancy fees;

    4. Legal fees; and

    5. Reimbursements.

    Includes amounts paid to entities associated with the Directors.

    Non-cash financing and investing activities

    1. Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows

    2. Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest

    Financing facilities available

    Add notes as necessary for an understanding of the position.

    Amount available

    $A'000

    Amount used

    $A'000

    -

    -

    -

    -

    1. Loan facilities

    2. Credit standby arrangements

    Reconciliation of cash

    Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows.

    Current quarter

    $A'000

    Previous quarter

    $A'000

    1. Cash on hand and at bank

    2. Deposits at call

    3. Bank overdraft

    4. Other (provide details)

    2,544

    2,681

    -

    -

    -

    -

    -

    -

    Total: cash at end of quarter (item 1.23)

    2,544

    2,681

    Acquisitions and disposals of business entities

    Acquisitions

    (Item 1.9(a))

    Disposals

    (Item 1.10(a))

    -

    -

    -

    -

    -

    -

    -

    -

    -

    -

    1. Name of entity

    2. Place of incorporation or registration

    3. Consideration for acquisition or disposal

    4. Total net assets

    5. Nature of business

    Compliance statement

    1. This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Act (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.

    2. This statement does give a true and fair view of the matters disclosed.

    Sign here: Date: 29th April 2016

    (Director) Print name: Tony Keating

    ResApp Health Limited issued this content on 29 April 2016 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 29 April 2016 09:11:24 UTC

    Original Document: http://www.resapphealth.com.au/wp-content/uploads/2016/04/RAP-Appendix-4C-qtr-ended-31-March-2016-v2.pdf